Abstract
Atogepant (Aquipta) is a new oral CGRP‐receptor antagonist indicated for the prophylaxis of migraine in adults. This article discusses its indication, efficacy and adverse effects.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have